Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~5 days
Time for 50 % to be eliminated
Steady State
~21.6 days
≈ 4.3 half-lives
Accumulation
×1.61
Cmax at steady state ÷ Cmax first dose
Gone After
~35 days
after last dose
Source: Mounjaro US Prescribing Information, August 2026, section 12.3: the formulated subcutaneous medicine has an elimination half-life of approximately five days. The label describes similar pharmacokinetics in healthy subjects and patients with type 2 diabetes. This product-specific reference replaces a generic SURPASS-1 attribution and does not establish research-material equivalence.. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Tirzepatide: ~5 days.
Tirzepatide has a reported half-life of about 5 days. Under a weekly dosing schedule, steady state is reached at roughly 4.3 half-lives — about 22 days — and subsequent doses accumulate by a factor of about 1.6 over a single dose.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 35 days — seven half-lives.
Tirzepatide is a dual GLP-1/GIP receptor agonist studied at weekly doses of 2.5 to 15 mg. Its 5-day half-life is shorter than semaglutide, resulting in slightly less accumulation and a faster approach to steady state under the same weekly interval.
Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~5 days
Time for 50 % to be eliminated
Steady State
~21.6 days
≈ 4.3 half-lives
Accumulation
×1.61
Cmax at steady state ÷ Cmax first dose
Gone After
~35 days
after last dose
Source: Mounjaro US Prescribing Information, August 2026, section 12.3: the formulated subcutaneous medicine has an elimination half-life of approximately five days. The label describes similar pharmacokinetics in healthy subjects and patients with type 2 diabetes. This product-specific reference replaces a generic SURPASS-1 attribution and does not establish research-material equivalence.. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Tirzepatide: ~5 days.
Tirzepatide has a reported half-life of about 5 days. Under a weekly dosing schedule, steady state is reached at roughly 4.3 half-lives — about 22 days — and subsequent doses accumulate by a factor of about 1.6 over a single dose.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 35 days — seven half-lives.
Tirzepatide is a dual GLP-1/GIP receptor agonist studied at weekly doses of 2.5 to 15 mg. Its 5-day half-life is shorter than semaglutide, resulting in slightly less accumulation and a faster approach to steady state under the same weekly interval.